The acquisition transforms GLMD from a clinical-stage biopharma into a commercial-stage medtech platform with a CE-marked product ready for European launch. Monitor Q2 2026 closing, initial European commercial traction in DACH countries, and enrollment updates from the U.S. pivotal trial. The $6M planned investment over 24 months provides a clear catalyst timeline.
Price Chart
Executive Summary
Galmed Pharmaceuticals (GLMD) entered into a definitive agreement to acquire Colospan Ltd., a medical device company with a CE-marked intraluminal bypass device (CG-100) for colorectal anastomotic leak prevention. The total consideration is $4.5 million, comprising $2.5 million in cash and $2.0 million in GLMD ordinary shares. The acquisition positions Galmed as a GI-focused medtech and biopharma platform, with Colospan's CG-100 targeting a $6 billion market. The transaction is expected to close in Q2 2026.
Key Facts
- Galmed to acquire Colospan for $4.5M total consideration ($2.5M cash + $2.0M in GLMD shares).
- Colospan's CG-100 intraluminal bypass device is CE marked under MDR, has FDA Breakthrough Device Designation, and is in an active U.S. pivotal IDE trial.
- Galmed plans to invest at least $6M over 24 months post-closing to launch CG-100 in Europe (DACH countries) in H2 2026.
- Colospan's CG-100 targets a $6 billion total addressable market for colorectal anastomotic leak prevention.
- 7.5% of cash and shares placed in escrow for 12 months; Colospan options and warrants cancelled at closing.
- Colospan shareholders receiving shares are subject to a 24-month lock-up and must grant an irrevocable proxy to Galmed's board.
- Colospan had $910K cash, $3.727M in convertible SAFE notes, and an accumulated deficit of $16.52M as of Dec 31, 2025.
- Colospan has not generated any revenue; its auditor's report includes a going concern qualification.
Financial Impact
Total consideration of $4.5 million ($2.5M cash + $2.0M in shares). Galmed had $18.6M in total assets and $15.8M in stockholders' equity as of Dec 31, 2025. Pro forma combined cash is $2.1M. Goodwill and intangible assets of $4.2M recorded.
Risk Factors
- Transaction may not close if conditions (including Section 341 shareholder approval) are not met.
- Colospan's pivotal trial has enrolled only 57 of 228 target patients (17%) and has experienced prior delays and a voluntary pause.
- CG-100 faces entrenched competition from the standard-of-care diverting stoma and emerging intraluminal bypass startups (Safeheal, Averto Medical, JSR Medical).
- Colospan has no revenue history and a going concern qualification; post-acquisition cash burn may require additional financing.
- Integration risk: Galmed has no medtech commercialization experience.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-027640 |
| Exhibit: ex99-1.htm | 0001493152-26-027640 |
| Exhibit: ex99-2.htm | 0001493152-26-027640 |
| Exhibit: ex99-4.htm | 0001493152-26-027640 |
| Exhibit: ex23-1.htm | 0001493152-26-027640 |
| Document: form6-k.htm | 0001493152-26-027640 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | 6-K | $4.63 $3.63 | ▼ −21.71% | ▼ −21.37% | — |
Sep 4, 2026 7w ago | EFFECT | $3.88 $4.63 | ▼ −19.33% | ▼ −20.54% | — |
Sep 3, 2026 7w ago | 6-K | $3.88 $4.63 | ▲ +19.33% | ▲ +20.54% | — |
Sep 2, 2026 7w ago | 6-K | $3.92 $4.63 | ▲ +18.11% | ▲ +19.26% | — |
Aug 19, 2026 9w ago | 6-K | $4.77 $4.33 | ▼ −9.22% | ▼ −8.84% | — |
Aug 17, 2026 10w ago | 6-K | $0.5134 | awaiting T+5 | — | — |
Jul 28, 2026 12w ago | 6-K | $0.5340 $0.5754 | ▲ +7.75% | ▲ +3.64% | — |
Jul 16, 2026 14w ago | 6-K | $0.5501 $0.5530 | ▲ +0.53% | ▲ +2.20% | — |
Jun 22, 2026 18w ago | 6-K | $0.5641 $0.5709 | ▲ +1.21% | ▲ +1.66% | — |
Jun 8, 2026 20w ago | 6-K | $0.4693 $0.6160 | ▲ +31.26% | ▲ +29.15% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers